Jazz Pharmaceuticals plc (JAZZ)

109.27 +2.17 (+2.03%) At close: 04:00PM EDT

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road
Dublin D04 E5W7
Ireland
353 1 634 7800
https://www.jazzpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2,800

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Bruce C. Cozadd	Co-Founder, Chairman & CEO	2.45M	13.66M	1964
Ms. Reneé D. Galá	President & COO	1.13M	N/A	1972
Dr. Robert Iannone M.D.	Executive VP and Global Head of Research & Development	1.08M	N/A	1967
Mr. Philip L. Johnson	Executive VP & CFO	N/A	N/A	N/A
Ms. Patricia Carr	Senior VP & Chief Accounting Officer	N/A	N/A	1972
Ms. Andrea N. Flynn Ph.D.	VP & Head of Investor Relations	N/A	N/A	N/A
Ms. Neena M. Patil J.D.	Executive VP & Chief Legal Officer	331.61k	N/A	1976
Ms. Heidi Manna	Executive VP & Chief People Officer	N/A	N/A	1972
Dr. Jed Black M.D.	Senior Vice President of Sleep & CNS Medicine	N/A	N/A	N/A
Ms. Samantha Pearce	Senior Vice President of Europe & International	N/A	N/A	1966

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Corporate governance

Jazz Pharmaceuticals plc’s ISS governance QualityScore as of 1 April 2024 is 3. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.